COMPANY

Molecular Express, Inc.

HQ: Rancho Dominguez, CA source · molecularexpress.com ↗

Location: Rancho Dominguez, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

50NIH grants

Timeline

May 6, 2025 Grant Government grant — SBIR: $999,784 (annual award, as published), announced May 6, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗

Funding

Last 2 years.

May 6, 2025 Government grant — SBIR: $999,784 (annual award, as published), announced May 6, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗

NIH awards 50

Annual award amounts. Total $37.1M.

May 8, 2024 NIH award 1R44HL172526-01A1 FY2024: $999,853 awarded for that fiscal year; activity R44 (SBIR); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. Preclinical Development of a ME-100 source ↗
2024 NIH contract (government contract; not a grant and not an investment round) 75N93024C00017-0-9999-1 FY2024: $2,999,352 awarded for that fiscal year; activity N01 (OTHER_NIH); PI HO, SAMON; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. VE source ↗
2024 NIH contract (government contract; not a grant and not an investment round) 75N93024C00018-0-9999-1 FY2024: $1,999,866 awarded for that fiscal year; activity N44 (OTHER_NIH); PI HO, SAMON; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. De source ↗
Jan 13, 2023 NIH award 5R43AI167312-02 FY2023: $299,779 awarded for that fiscal year; activity R43 (SBIR); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. VesiVax Vaccine Formulation Against N source ↗
2023 NIH contract (government contract; not a grant and not an investment round) 75N93023C00033-0-9999-1 FY2023: $599,925 awarded for that fiscal year; activity N43 (OTHER_NIH); PI ONHO, SAM; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. DEVE source ↗
Aug 1, 2022 NIH award 3R44HL154968-02S2 FY2022: $113,400 awarded for that fiscal year; activity R44 (SBIR); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. Non-clinical Development of a Synth source ↗
Jul 28, 2022 NIH award 3R44HL154968-02S1 FY2022: $67,200 awarded for that fiscal year; activity R44 (SBIR); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. Non-clinical Development of a Synthe source ↗
Jul 8, 2022 NIH award 1R43AI167394-01 FY2022: $298,479 awarded for that fiscal year; activity R43 (SBIR); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. Niclosamide Formulations for the Trea source ↗
Jun 6, 2022 NIH award 5R44HL154968-02 FY2022: $1,031,789 awarded for that fiscal year; activity R44 (SBIR); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. Non-clinical Development of a Synth source ↗
Feb 17, 2022 NIH award 1R43AI167312-01 FY2022: $299,817 awarded for that fiscal year; activity R43 (SBIR); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. VesiVax Vaccine Formulation Against N source ↗
2022 NIH contract (government contract; not a grant and not an investment round) 75N93022C00012-0-9999-1 FY2022: $300,000 awarded for that fiscal year; activity N43 (OTHER_NIH); PI FUJI, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. Ves source ↗
2022 NIH contract (government contract; not a grant and not an investment round) 75N93021C00027-P00003-9999-1 FY2022: $1,994,571 awarded for that fiscal year; activity N44 (OTHER_NIH); PI ON HO, SAM; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, source ↗
Jun 16, 2021 NIH award 1R44HL154968-01A1 FY2021: $956,889 awarded for that fiscal year; activity R44 (SBIR); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. Non-clinical Development of a Synth source ↗
2021 NIH contract (government contract; not a grant and not an investment round) 75N93021C00039-0-9999-1 FY2021: $569,807 awarded for that fiscal year; activity N43 (OTHER_NIH); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. DE source ↗
2021 NIH contract (government contract; not a grant and not an investment round) 75N93021C00027-0-9999-1 FY2021: $299,994 awarded for that fiscal year; activity N43 (OTHER_NIH); PI ON HO, SAM; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. Dev source ↗
2020 NIH contract (government contract; not a grant and not an investment round) 75N93020C00010-0-9999-1 FY2020: $299,961 awarded for that fiscal year; activity N43 (OTHER_NIH); PI ON HO, SAM; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. Eva source ↗
2020 NIH contract (government contract; not a grant and not an investment round) 75N93020C00012-0-9999-1 FY2020: $299,993 awarded for that fiscal year; activity N43 (OTHER_NIH); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. De source ↗
2019 NIH contract (government contract; not a grant and not an investment round) 75N93019C00007-0-9999-1 FY2019: $599,983 awarded for that fiscal year; activity N43 (OTHER_NIH); PI HO, SAM; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. Evalua source ↗
Jun 26, 2018 NIH award 5R44AI115828-03 FY2018: $497,338 awarded for that fiscal year; activity R44 (SBIR); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. Development of a Vaccine for the Prev source ↗
2018 NIH contract (government contract; not a grant and not an investment round) 272201800053C-0-0-1 FY2018: $213,800 awarded for that fiscal year; activity N01 (OTHER_NIH); PI n/a; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. Mucosal Vaccin source ↗
Jul 14, 2017 NIH award 5R44AI094770-04 FY2017: $736,747 awarded for that fiscal year; activity R44 (SBIR); PI HO, SAMON; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. The VesiVax® System: Vaccine Developmen source ↗
Jun 28, 2017 NIH award 2R44AI115828-02 FY2017: $934,456 awarded for that fiscal year; activity R44 (SBIR); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. Development of a Vaccine for the Prev source ↗
Feb 7, 2017 NIH award 1R43AI131788-01 FY2017: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. VesiVax® Peanut Allergy Immunotherapy source ↗
2017 NIH contract (government contract; not a grant and not an investment round) 272201700081C-0-0-1 FY2017: $296,286 awarded for that fiscal year; activity N01 (OTHER_NIH); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. DELIVE source ↗
Jul 29, 2016 NIH award 3R42DA040422-01S1 FY2016: $95,143 awarded for that fiscal year; activity R42 (STTR); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. Pre-clinical Development of a Vaccin source ↗
Jul 20, 2016 NIH award 2R44AI094770-03A1 FY2016: $762,253 awarded for that fiscal year; activity R44 (SBIR); PI HO, SAMON; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. The VesiVax® System: Vaccine Developm source ↗
Mar 15, 2016 NIH award 1R43AI124725-01 FY2016: $225,000 awarded for that fiscal year; activity R43 (SBIR); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. Optimization of VesiVax® Lipidated Tu source ↗
2016 NIH contract (government contract; not a grant and not an investment round) 272201600032C-0-0-1 FY2016: $440,933 awarded for that fiscal year; activity N01 (OTHER_NIH); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. DEVE source ↗
Sep 1, 2015 NIH award 1R42DA040422-01 FY2015: $225,033 awarded for that fiscal year; activity R42 (STTR); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. Pre-clinical Development of a Vaccine source ↗
Aug 20, 2015 NIH award 1R41TR001338-01 FY2015: $322,946 awarded for that fiscal year; activity R41 (STTR); PI FUJII, GARY; recipient as written: MOLECULAR EXPRESS, INC., RANCHO DOMINGUEZ, CA. Development of a Gene and Oligonucleo source ↗